Ketamine has been shown to relieve depression-like symptoms in animal studies. With human volunteers, researchers Sounak Mohanta and Yuri Saalmann concluded that the drug blocks “negative predictions” that are prominent in depressed patients.
The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma.
They are among the first sites in the country to study whether an investigational vaccine developed by the pharmaceutical company AstraZeneca can prevent the disease.
A survey of 132 hospitals found that the delays could reduce the likelihood that drug companies will develop new antibiotics essential for treating diseases.
An interdisciplinary team of investigators from UW–Madison and Ohio State believes once the new approach to maintaining open blood vessels is fully developed, it could benefit millions of patients.
Inflammation “is likely implicated in almost every disease,” says researcher David Beebe — including cancer, cardiovascular conditions and autoimmune diseases.
To help physicians choose the best antibiotic first, researchers in the School of Pharmacy and the State Cartographer’s Office are drawing inspiration from the weather.
The need for an Ebola vaccine is acute. Periodic outbreaks of the disease in sub-Saharan Africa, including an epidemic between 2013 and 2016, caused major loss of life and serious economic disruption.
An increase in the proportion of the population that is undocumented is associated with fewer drug arrests, drunken driving arrests and drug overdoses.
An engineering team has developed a new way to seed biomedical devices with agents that promote tissue growth and healing.
The Precision Medicine Molecular Tumor Board has a dual mission: consulting with oncologists statewide about targeted drugs to battle out-of-control cancers; and amassing data on what works and what does not.
A Morgridge Institute for Research team has unleashed a fast, simple and predictive text-mining tool that may turbocharge big biomedical pursuits such as drug repurposing and stem cell treatments.
The new method gives chemists prospecting for bioactive molecules a new tool in the search for novel drugs or chemicals for agriculture.
Two specific toxins — including the popular drug Botox — have multiple uses for treating many neuromuscular conditions, including frown lines, disabling muscle spasms and migraine headaches.
The results were surprising due to the breadth of the different proteins found to be involved, says biochemist Douglas Weibel.
As “the female Viagra” comes to market, researchers are learning more about how the drug affects the brain.
A University of Wisconsin-Madison physician and her research team have shown that a heart medication can prevent ovarian damage and improve survival in adolescent mice after chemotherapy. The treatment also increased the number of their healthy offspring.
The garden of traditional medicinal plants at the entrance of Rennebohm Hall on the University of Wisconsin-Madison campus shows the deep plant roots of pharmaceuticals, says former Dean Jeanette Roberts, a professor of pharmacy.
A new system developed by scientists at the Morgridge Institute for Research and the University of Wisconsin-Madison may provide a faster, cheaper and more biologically relevant way to screen drugs and chemicals that could harm the developing brain.
Antibodies are specific molecules that can lock onto a particular cellular structure to start, stop or otherwise temper a biological process. Because they are so specific, antibodies are at the forefront of drug discovery. So drug companies want a faster route to step one: identifying which of the millions of possible antibodies will work against molecules that cause disease.